IBDEI0EX ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7206,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7206,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,7206,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,7206,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,7207,0)
 ;;=180.9^^55^577^29
 ;;^UTILITY(U,$J,358.3,7207,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7207,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,7207,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,7207,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,7208,0)
 ;;=203.02^^55^577^104
 ;;^UTILITY(U,$J,358.3,7208,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7208,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,7208,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,7208,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,7209,0)
 ;;=204.02^^55^577^2
 ;;^UTILITY(U,$J,358.3,7209,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7209,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,7209,1,5,0)
 ;;=5^ALL,In Relapse
 ;;^UTILITY(U,$J,358.3,7209,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,7210,0)
 ;;=204.12^^55^577^17
 ;;^UTILITY(U,$J,358.3,7210,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7210,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,7210,1,5,0)
 ;;=5^CLL,In Relapse
 ;;^UTILITY(U,$J,358.3,7210,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,7211,0)
 ;;=204.20^^55^577^114
 ;;^UTILITY(U,$J,358.3,7211,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7211,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,7211,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,7211,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,7212,0)
 ;;=204.21^^55^577^116
 ;;^UTILITY(U,$J,358.3,7212,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7212,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,7212,1,5,0)
 ;;=5^Subacute LL,In Remission
 ;;^UTILITY(U,$J,358.3,7212,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,7213,0)
 ;;=204.22^^55^577^115
 ;;^UTILITY(U,$J,358.3,7213,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7213,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,7213,1,5,0)
 ;;=5^Subacute LL,In Relapse
 ;;^UTILITY(U,$J,358.3,7213,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,7214,0)
 ;;=205.02^^55^577^5
 ;;^UTILITY(U,$J,358.3,7214,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7214,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,7214,1,5,0)
 ;;=5^AML,In Relapse
 ;;^UTILITY(U,$J,358.3,7214,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,7215,0)
 ;;=205.12^^55^577^20
 ;;^UTILITY(U,$J,358.3,7215,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7215,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,7215,1,5,0)
 ;;=5^CML,In Relapse
 ;;^UTILITY(U,$J,358.3,7215,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,7216,0)
 ;;=284.81^^55^577^14
 ;;^UTILITY(U,$J,358.3,7216,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7216,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,7216,1,5,0)
 ;;=5^Aplastic Anemia d/t Drugs
 ;;^UTILITY(U,$J,358.3,7216,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,7217,0)
 ;;=284.89^^55^577^13
 ;;^UTILITY(U,$J,358.3,7217,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7217,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,7217,1,5,0)
 ;;=5^Aplastic Anemia d/t Chronic Disease
 ;;^UTILITY(U,$J,358.3,7217,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,7218,0)
 ;;=289.84^^55^577^119
 ;;^UTILITY(U,$J,358.3,7218,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7218,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,7218,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,7218,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,7219,0)
 ;;=V10.91^^55^577^67
 ;;^UTILITY(U,$J,358.3,7219,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7219,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,7219,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,7219,2)
 ;;=^338494
